Search
Moleculin Biotech Inc
MBRXAdd to Watchlist
0.780USD
+0.005+0.65%
Market hours 09/15, 11:25（ET）
5.54MMarket Cap
LossP/E TTM
Moleculin Biotech Inc (MBRX) Stock Price Target & Forecast
Analyst Rating
Based on 3 analysts giving stock ratings to Moleculin Biotech Inc in the past month.
Buy
0 Strong Buy
3 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
12.000USD+1578.32%
MBRX Analyst Recommendation Trends
In the current month, MBRX has received 3 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. MBRX average Analyst price target in the last month is 12.000.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
0
0
0
0
0
0
0
0
3
3
3
3
3
3
3
3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3
3
3
3
3
3
3
3
MBRX Analyst Rating for Peer Comparison
Updated: Sep 14, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
IQVIA Holdings Inc
IQV
7
12
6
0
0
25
CRISPR Therapeutics AG
CRSP
4
9
11
0
0
24
Insmed Inc
INSM
7
17
0
0
0
24
Kymera Therapeutics Inc
KYMR
8
13
2
0
0
23
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Revolution Medicines Inc
RVMD
8
12
1
0
0
21
Ascendis Pharma A/S
ASND
10
10
0
0
0
20
Financial Forecasting
Based on analysts' estimates, MBRX EPS is projected to reach -0.650 in FY2026Q3, following reported EPS of -1.402 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-6.11
-1.66
-1.55
-0.65
-0.36
Actual
6.90
-3.54
-1.40
--
--
Surprise
+212.86%
-112.96%
+9.75%
--
--
FAQs
What is Moleculin Biotech Inc's price target?
Analysts forecast that Moleculin Biotech Inc's price target is USD 12.00, with the highest forecast at USD 31.00 and the lowest forecast at USD 2.00.
How have Moleculin Biotech IncMBRX's recent earnings per share performed?
The market expectation was USD -1.40, while Moleculin Biotech IncMBRX's earnings per share (EPS) for the previous quarter was USD -3.54. EPS for the next quarter is expected at USD -0.65.
What is the analyst rating for Moleculin Biotech Inc?
Based on the ratings of Moleculin Biotech Inc's stock from 3 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.